Reuters logo
BRIEF-Noxxon provides update on ongoing phase 1/2 clinical trial with lead program NOX-A12
September 28, 2017 / 6:30 AM / 2 months ago

BRIEF-Noxxon provides update on ongoing phase 1/2 clinical trial with lead program NOX-A12

Sept 28 (Reuters) - NOXXON PHARMA NV:

* NOXXON PROVIDES UPDATE ON ONGOING PHASE 1/2 CLINICAL TRIAL WITH LEAD PROGRAM NOX-A12

* ‍INITIAL DATA SUPPORTS PENETRATION OF NOX-A12 INTO TUMOR TISSUE

* ‍INITIAL DATA SUPPORTS PREVIOUSLY ESTABLISHED SAFETY PROFILE OF NOX-A12 MONOTHERAPY IN COLORECTAL AND PANCREATIC CANCER PATIENTS​

* ‍TRIAL REMAINS ON SCHEDULE TO DELIVER TOP-LINE BIOPSY ANALYSIS IN SECOND AND FOURTH QUARTERS OF 2018 RESPECTIVELY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below